{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:12:20Z","timestamp":1791396740246,"version":"4.3.3"},"reference-count":31,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,8,17]],"date-time":"2010-08-17T00:00:00Z","timestamp":1282003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Management of severe insulin resistance (IR) is a major clinical challenge in many patients with obesity or lipodystrophy, and also in rarer patients with proven or suspected genetic defects in the insulin receptor or downstream signalling. The latter group can present at any time between birth and early adult life, with a variable clinical course broadly correlated with the severity of IR. Primary insulin signalling defects are usually associated with poor weight gain rather than obesity. Initially, extreme hyperinsulinaemia produces ovarian enlargement and hyperandrogenism in women, and often fasting or postprandial hypoglycaemia. However, any hypoglycaemia gradually evolves into insulin\u2010resistant hyperglycaemia when beta cell function declines. Optimal management of these complex disorders depends on early diagnosis and appropriate targeting of both high and low glucose levels. In newborns, continuous nasogastric feeding may reduce harmful glycaemic fluctuations, and in older patients, acarbose may mitigate postprandial hypoglycaemia. Insulin sensitization, initially with metformin but later with trials of additional agents such as thiazolidinediones, is the mainstay of early therapy, but insulin replacement, eventually with very high doses, is required once diabetes has supervened. Preliminary data suggest that rhIGF\u20101 can improve survival in infants with the most severe insulin receptor defects and also improve beta cell function in older patients with milder receptoropathies. The utility of newer therapies such as glucagon\u2010like peptide\u20101 agonists and dipeptidyl peptidase\u2010IV inhibitors remains untested in this condition. Thus, management of these patients remains largely empirical, and there is a pressing need to collate data centrally to optimize treatment algorithms.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2010.03810.x","type":"journal-article","created":{"date-parts":[[2010,4,23]],"date-time":"2010-04-23T09:27:03Z","timestamp":1272014823000},"page":"286-290","source":"Crossref","is-referenced-by-count":46,"title":["CLINICAL QUESTION: What is the best management strategy for patients with severe insulin resistance?"],"prefix":"10.1111","volume":"73","author":[{"given":"Robert K.","family":"Semple","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Dunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,17]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-007-0784-z"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0801652"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2409"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.12.4390"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000133625.73570.54"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra025261"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1502-9"},{"key":"e_1_2_6_9_2","volume-title":"Oxford Textbook of Endocrinology and Diabetes","author":"Semple R.K.","year":"2010"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-48-3-495"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.7.3319"},{"key":"e_1_2_6_12_2","unstructured":"http:\/\/www.cuh.org.uk\/addenbrookes\/services\/clinical\/genetics\/labs\/labs_index.html."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-374430-2.00004-3"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0271"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2337\/diab.42.5.696","article-title":"Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes","volume":"42","author":"Kuzuya H.","year":"1993","journal-title":"Diabetes"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199011153232016"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00400998"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.2.542"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050695"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.79.3.799"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1360475"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.5.1240"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1410177"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031952"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197604012941401"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-2194"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0166"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.2337\/db06-1665"},{"key":"e_1_2_6_29_2","first-page":"315","article-title":"Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis","volume":"119","author":"Semple R.K.","year":"2009","journal-title":"Journal of Clinical Investigation"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc05-1249"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2001.00898.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2088"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2010.03810.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2010.03810.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T15:05:51Z","timestamp":1697382351000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2010.03810.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,17]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1111\/j.1365-2265.2010.03810.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2010.03810.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,17]]}}}